申请人:Dalhousie University
公开号:US20020049330A1
公开(公告)日:2002-04-25
This invention relates to a compound of formula I:
1
or a pharmaceutically acceptable salt thereof;
in which preferably R
3
, R
4
and R
6
are each hydrogen;
X is C═O or CH
2
; and
R
7
and R
8
are each independently selected from the group consisting of hydrogen, (C
1
-C
12
)alkyl, (C
3
-C
8
)cycloalkyl and (C
1
-C
2
)alkyl(C
6
-C
14
)aryl; or
R
7
and R
8
when taken together form a (C
2
-C
7
)alkylene group; or
—NR
7
R
8
together forms a (C
2
-C
14
)heterocyclic or substituted (C
2
-C
14
)heterocyclic. Such compounds modulate the activity of serine hydrolases and can be used in pharmaceutical compositions for the treatment of Alzheimer's disease.
这项发明涉及一种化合物,其化学式为I:1或其药用盐;其中,最好的情况是R3、R4和R6分别为氢;X为C═O或CH2;而R7和R8分别独立地选自氢、(C1-C12)烷基、(C3-C8)环烷基和(C1-C2)(C6-C14)芳基的组合;或者当R7和R8一起形成(C2-C7)烷基基团时;或者—NR7R8一起形成(C2-C14)杂环或取代的(C2-C14)杂环。这些化合物调节丝氨酰水解酶的活性,可用于治疗阿尔茨海默病的药物组合物中。